Drug intelligence / Profile preview

OBN41A

Development stage: Preclinical
Lead developer: Oxford BioTherapeutics

Overview

OBN41A is a discovery-stage oncology asset being developed by Oxford BioTherapeutics for the treatment of solid tumors. The program is currently identified as a partnered asset within the company's pipeline. While specific details regarding its molecular target and modality remain undisclosed, Oxford BioTherapeutics generally focuses on the development of targeted therapies, such as antibody-drug conjugates (ADCs) and T-cell engagers (TCEs), leveraging their proprietary OGAP® (Oxford Genome Anatomy Project) platform to identify novel tumor-associated antigens.

Beyond the preview

Go deeper on OBN41A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBN41A.

Explore the full profile